drugset / Trial / NCT03672292
Evaluate Safety and Efficacy of the Coadministration of Ibrexafungerp With Voriconazole in Patients With Invasive Pulmonary Aspergillosis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Study to evaluate the safety and efficacy of coadminstration of SCY-078 with a mold-active azole (voriconazole) compared to voriconazole in patients with invasive pulmonary aspergillosis.
Timeline
- Start
- 2019-01-22
- Primary completion
- 2023-03-27
- Completion
- 2023-03-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ibrexafungerp | Small molecule | 500 mg | Oral |
| Subject | Voriconazole | Small molecule | 4 mg/kg | Intravenous |
| Subject | Voriconazole | Small molecule | 200 mg | Intravenous |